DEA inspections, accountability audits, administrative subpoenas, registration defense, and controlled-substance enforcement matters
A Drug Enforcement Administration (DEA) visit to a compounding pharmacy can look routine at first. Investigators may ask to inspect records, count controlled substances, or begin an accountability audit. Some visits end there. Others become the first visible step in a broader inquiry that the pharmacy did not know was underway.
Compounding adds layers that can make a DEA review more complicated. Controlled substances may move through receiving, weighing, compounding, batch production, wastage, finished dosage forms, dispensing, transfers, returns, and destruction. DEA may also be examining a particular prescriber, a telemedicine relationship, practitioner-office supply, or whether the pharmacy’s registration structure matches what the business is actually doing. The rules that apply more broadly to pharmacies are discussed on Jani Law’s DEA Defense for Pharmacies page. This page focuses on the issues that become more complicated when the pharmacy compounds.
Dhairya Jani served as DEA Diversion Enforcement Counsel in the DEA Office of Chief Counsel, where he administratively prosecuted registration matters under the Controlled Substances Act. Jani Law PLLC now represents compounding pharmacies and other DEA registrants in investigations, inspections, administrative subpoenas, civil penalty matters, Orders to Show Cause, Immediate Suspension Orders, negotiated resolutions, and administrative hearings.
If DEA has contacted your compounding pharmacy, whether investigators are at the door, an accountability audit is underway, a records request or subpoena has arrived, or the pharmacy is facing a proposed Memorandum of Agreement or an Order to Show Cause, Jani Law PLLC offers a free, confidential consultation. Call 202-899-2711 or contact Jani Law PLLC.
Common Reasons Compounding Pharmacies Contact Jani Law
Compounding pharmacies often reach out when one of these issues has already surfaced:
- DEA Diversion Investigators arrived for an inspection or presented a Notice of Inspection (DEA Form 82).
- An accountability audit has begun and the numbers do not reconcile.
- Investigators identified an apparent shortage, overage, inventory discrepancy, loss, or recordkeeping issue.
- The pharmacy received an administrative subpoena involving the pharmacy, patients, prescribers, or a telemedicine platform.
- DEA is asking about a particular prescriber, controlled substance, compounded formulation, or pattern of dispensing.
- The pharmacy is being questioned about practitioner-office supply, transfers to other registrants, or its DEA registration category.
- DEA has raised potential Controlled Substances Act violations, proposed a Memorandum of Agreement, pursued civil penalties, or served an Order to Show Cause or Immediate Suspension Order.
DEA Is Inspecting Your Compounding Pharmacy: What Does That Mean?
On the day investigators arrive, a routine regulatory review and the opening step of a larger investigation can look very similar. The difference often becomes clearer only after investigators review the records, compare the inventory, and begin asking more focused questions.
DEA personnel conducting an administrative inspection generally present credentials and written inspection authority and state the purpose of the inspection. The agency’s Notice of Inspection is DEA Form 82. That first contact may not reveal what information DEA already has, whether another person or entity is part of the inquiry, or what issues may emerge after the records are reviewed.
For a pharmacy owner or pharmacist-in-charge (PIC), the practical concern is timing: by the time DEA becomes visible to the pharmacy, investigative work may already have occurred elsewhere, and the inspection itself can uncover issues that expand the scope of the matter.
The Accountability Audit: Where Compounding Pharmacies Get Complicated
A Diversion Investigator may begin with a physical count and a defined audit period. The arithmetic sounds straightforward. Applying it to a compounding operation often is not. The analysis may turn on questions such as:
- Was the opening inventory accurate?
- Were all controlled-substance receipts included?
- Were transfers, returns, destructions, and documented losses captured?
- Were units converted consistently?
- How were actual batch yields and wastage reflected?
- Do relevant records live in more than one inventory, compounding, dispensing, or shipping system?
An apparent discrepancy may be significant, but the first number is not necessarily the final answer. The audit period, source records, units, yield assumptions, and data pulled from different systems may all affect what the variance actually represents.
Facing an apparent inventory discrepancy in a DEA accountability audit? A consultation can focus on how the audit was constructed, what records support the variance, and what issues may require closer review. Call 202-899-2711 or contact Jani Law PLLC.
How a DEA Inspection Can Expand Into a Broader Pharmacy Investigation
A compounding-pharmacy inspection can widen when the review raises questions that cannot be resolved from the records initially produced. Examples can include an unexplained inventory variance, missing required records, inconsistent explanations, or a prescribing or dispensing pattern that warrants additional scrutiny.
When that happens, follow-up may include a broader audit period, additional records requests, employee interviews, or an administrative subpoena. Public enforcement matters involving pharmacies and compounding operations illustrate the larger point: a regulatory inspection can develop into a civil or administrative enforcement matter when the records or transactions raise additional Controlled Substances Act issues. One DOJ matter provides an example.
What DEA May Examine at a Compounding Pharmacy
The scope depends on the reason for the visit and what investigators encounter. Common areas can include:
Inventory and accountability
Beginning inventory, receipts, dispensing, distribution, transfers, destruction, reported losses, and ending physical inventory may all be compared. For compounded products, ingredient quantities, batch yields, unit conversions, and wastage can become part of the reconstruction.
Schedule II ordering
DEA may compare DEA Form 222 or Controlled Substance Ordering System (CSOS) records with what the pharmacy received and entered into inventory.
Initial and biennial inventories
Federal regulations require initial and biennial inventories. Investigators may examine whether required inventories are complete, accurate, and associated with the appropriate registered location.
Prescription files and prescriber relationships
DEA may review prescription files, dispensing patterns, pharmacist documentation, and the information available to the pharmacy about a prescriber or prescribing model at the time of dispensing.
Theft, significant loss, and security
The review may include physical security, access controls, how discrepancies were escalated internally, and whether a theft or significant loss was identified and reported under the applicable rules.
Written policies compared with actual practice
Policies matter, but investigators may also compare them with employee practices and the pharmacy’s records. A gap between a written standard operating procedure and what actually occurred can become part of the enforcement record.
When DEA Starts Looking at the Prescriptions, Not Just the Inventory
DEA pharmacy matters can move from inventory records into prescription files. Under 21 C.F.R. § 1306.04(a), pharmacists have a corresponding responsibility in the dispensing of controlled substances. When DEA reviews the prescription files, the questions become highly fact-specific:
- What information was available to the pharmacist when the prescription was filled?
- What concerns, if any, arose from the prescription or prescribing pattern?
- What verification or follow-up occurred?
- What does the contemporaneous record show about the dispensing decision?
For a compounding pharmacy, those questions may become especially important when the business serves a concentrated prescriber network, ships across a wide geographic area, or fills controlled-substance prescriptions generated through telemedicine.
DEA Corresponding Responsibility: What the Pharmacy’s Records May Show
Facts that raise questions about a controlled-substance prescription can lead DEA to examine the pharmacy’s dispensing decisions more closely. But concerns or so-called red flags are not, by themselves, the same as proving a Controlled Substances Act violation. The surrounding facts still matter: what raised the concern, what information was available, what the pharmacist learned, how the issue was evaluated, and what the record shows about the decision to dispense.
Why contemporaneous documentation matters
For a pharmacy already under review, the existing prescription record can become especially important. Investigators may look for documentation of prescriber communications, PDMP review, verification of patient or prescriber information, pharmacist notes, and other steps taken before dispensing.
Those records do not automatically establish that a prescription was appropriate or resolve every DEA concern. They can, however, help establish what information the pharmacist actually had, what questions were investigated, and how the dispensing decision was made at the time, rather than relying entirely on explanations developed after an investigation begins.
The government still has to prove the violation it alleges
A recent federal appeals court decision reinforced an important limit on DEA pharmacy enforcement. The court vacated a pharmacy revocation after concluding that the agency had not established that the prescriptions at issue were invalid when issued or that the pharmacist knew they were invalid. Warning signs and unresolved questions were not a substitute for proving the elements of the charged violation.
That ruling is controlling in Texas, Louisiana, and Mississippi and may be persuasive elsewhere. More broadly, it illustrates why a DEA pharmacy matter should be evaluated against the specific allegations, the governing law, and the record that existed when the prescriptions were filled, not simply against a list of circumstances the government views as suspicious.
How DEA evaluates the practitioner on the other side of the prescription can involve a different set of issues, discussed on Jani Law’s DEA Defense for Healthcare Prescribers page.
Compounded Ketamine, Telemedicine, and Prescriber Networks
Compounded ketamine is one example of how a pharmacy can become part of an inquiry that began with a prescriber, telemedicine platform, or treatment model. The pharmacy may not control the clinical encounter, but DEA can still examine the pharmacy’s own dispensing decisions, records, due diligence, and registration obligations.
As of September 2026, the temporary federal telemedicine flexibilities for controlled-substance prescribing remain extended through December 31, 2026. Those flexibilities address when qualifying telemedicine prescribing may occur without a prior in-person evaluation; they do not eliminate the pharmacy’s separate obligations under controlled-substance law and applicable state law. A proposed special registration framework for telemedicine, published in January 2025, remains pending and has not been finalized.
The provider side of the same issue is discussed on Jani Law’s DEA ketamine clinic defense page.
Does Your Compounding Model Fit Your DEA Registration?
Compounding alone does not answer the DEA registration question. The more useful analysis is whether the pharmacy’s actual controlled-substance activity fits the registration authority it currently holds.
FDA compounding status does not resolve the DEA registration analysis
Sections 503A and 503B are Food and Drug Administration (FDA) compounding pathways. They can be central to FDA compliance, but they do not by themselves determine whether particular controlled-substance activity is dispensing, distribution, or manufacturing for DEA purposes.
The Controlled Substances Act has its own manufacturing framework
The Controlled Substances Act defines “manufacture” broadly enough to include compounding while excluding certain qualifying practitioner activity when the statutory conditions are met. Whether a particular business model fits that framework can turn on facts such as:
- the controlled-substance activity actually being performed;
- the role of patient-specific dispensing or administration;
- the entities and DEA registrations involved;
- the locations where controlled substances are handled; and
- how the finished product moves to the ultimate recipient.
Office stock and transfers can raise a separate distribution question
DEA regulations also contain a limited pathway under 21 C.F.R. § 1307.11 for certain distributions by a practitioner without a separate distributor registration when the regulation’s conditions are satisfied. For a pharmacy supplying practitioner offices or other registrants, the volume, purpose, documentation, recipient, and overall business model can all become relevant.
Where those issues are central, the analysis may overlap with the DEA frameworks discussed on Jani Law’s pages for pharmaceutical manufacturers and drug distributors.
If DEA Identifies a Problem, What Could Happen Next?
Not every inspection leads to enforcement. When DEA identifies issues it wants to pursue, however, the matter can move in several directions.
More records, a broader audit, or additional interviews
Investigators may expand the audit period, request more records, interview employees, or ask for additional information about specific discrepancies or dispensing practices.
DEA administrative subpoena
A subpoena may seek pharmacy records or records concerning particular patients, prescribers, platforms, or transactions. Scope, privilege, certification, preservation, and production strategy can matter before records are produced. Jani Law’s guide to DEA administrative subpoenas discusses the process in more detail.
Civil penalties or a negotiated resolution
Controlled Substances Act civil penalties can be assessed on a per-violation basis, which can make repeated recordkeeping or dispensing allegations significant even when the underlying issue began with a limited set of records. Depending on the matter, DEA may also seek a negotiated resolution with ongoing reporting, audit, training, or operational requirements.
Order to Show Cause or Immediate Suspension Order
An Order to Show Cause begins formal DEA administrative litigation involving the registration. An Immediate Suspension Order can take effect immediately when DEA invokes the statutory imminent-danger standard. The posture, deadlines, and available options are different from an inspection or audit.
If an Order to Show Cause has already been served, Jani Law’s guide to the first thirty days after a DEA Order to Show Cause explains the transition from investigation to formal proceedings.
DEA Just Arrived at the Pharmacy: Questions Worth Clarifying Early
Every inspection is different, and a general webpage cannot tell a pharmacy how to respond to a particular visit. But several threshold questions can help frame what is happening and what may need closer review.
What authority is DEA using?
A consent-based administrative inspection, an administrative inspection warrant, and an administrative subpoena operate under different legal authorities. The documents presented at the outset help identify which process is underway.
What is the stated purpose and scope?
The stated purpose matters, but it may not reveal every piece of information already known to the agency or every issue that could emerge after the records are reviewed. Understanding what has actually been requested can help define the immediate scope of the visit.
Where are the relevant records?
At a compounding pharmacy, accountability information may exist across receiving, inventory, compounding, dispensing, shipping, and other systems. Locating the existing record and understanding how those systems connect can become important when investigators are attempting to reconstruct controlled-substance movement.
Who is communicating for the pharmacy?
Investigators may speak with owners, the PIC, staff pharmacists, technicians, or other personnel. Different employees can have different knowledge of the same process. How communications are handled may therefore become an important practical consideration in an active inspection.
Are there questions the pharmacy cannot answer accurately yet?
An apparent inventory variance or records issue may require reconstruction before its cause is understood. In an active matter, the distinction between what the pharmacy knows, what it is still evaluating, and what the records ultimately establish can be important.
Could different interests emerge?
The pharmacy, PIC, individual pharmacists, prescribers, owners, and affiliated businesses may not always have identical interests. A review focused initially on the pharmacy can later raise separate questions about individual conduct, prescribing decisions, or DEA registrations. Recognizing those differences early can matter to how representation and the response are structured.
When Should a Compounding Pharmacy Call DEA Regulatory Counsel?
A compounding pharmacy does not need to wait for an Order to Show Cause or a formal allegation before speaking with DEA regulatory counsel. In many matters, counsel can be most useful while investigators are still gathering records, conducting an accountability audit, or deciding what the facts may support.
A consultation may be particularly useful when:
- DEA arrives for an inspection and the pharmacy is uncertain about the authority, scope, or records being requested;
- an accountability audit identifies an apparent shortage, overage, or other variance that the pharmacy cannot readily reconcile;
- investigators begin asking focused questions about particular prescriptions, prescribers, compounded formulations, telemedicine relationships, or practitioner-office supply;
- DEA requests records or explanations beyond what the pharmacy expected from the initial inspection;
- the pharmacy receives an administrative subpoena involving its operations or records concerning a prescriber, patient group, telemedicine platform, supplier, or other business relationship;
- the pharmacy needs to assess whether its controlled-substance compounding, transfers, office-use supply, or distribution practices fit its existing DEA registration structure;
- the pharmacy is evaluating potential recordkeeping, inventory, security, dispensing, or corresponding-responsibility concerns and considering whether corrective action is appropriate; or
- DEA raises potential civil penalties, a Memorandum of Agreement, an Order to Show Cause, or an Immediate Suspension Order.
The value of involving counsel early is not to change the underlying facts. It is to understand what DEA is actually examining, separate verified facts from assumptions, evaluate the audit methodology or legal theory, and make sure the pharmacy responds from the complete record before preliminary conclusions harden into accepted findings.
If DEA is already reviewing your compounding pharmacy and you are trying to understand what an inspection, accountability audit, subpoena, or follow-up request may mean, Jani Law PLLC offers a free, confidential consultation. Call 202-899-2711 or contact Jani Law PLLC online.
What Is DEA Form 82?
DEA Form 82 is the agency’s Notice of Inspection of Controlled Premises. When DEA is seeking a consent-based administrative inspection, 21 C.F.R. § 1316.08 provides that informed consent includes notice of the right to refuse a warrantless administrative inspection and the ability to withdraw consent. What that means in a particular inspection depends on the facts and the authority DEA is using.
How Jani Law PLLC Helps in a Compounding Pharmacy DEA Matter
Some pharmacies call while investigators are still on site. Others call after an audit identifies an apparent discrepancy, after a subpoena arrives, or with a proposed Memorandum of Agreement or an Order to Show Cause already in hand. Jani Law PLLC represents pharmacies and other DEA registrants at each of those stages.
Inspection and accountability-audit response
Evaluating the inspection authority and scope, preserving and organizing the existing record, reconstructing the accountability calculation, and assessing what the apparent discrepancy establishes and what it does not.
Administrative subpoena response
Reviewing scope, legal authority, preservation, privilege, certification, production format, and whether explanatory context is appropriate.
Prescription-file and corresponding-responsibility defense
Reconstructing what information was available when prescriptions were filled, what verification occurred, what was documented, and whether the government’s theory fits the evidence and governing law.
Registration-structure analysis
Evaluating whether the pharmacy’s actual controlled-substance activity matches its DEA registration authority, including office-use transfers, distributions to other registrants, and activity that may raise manufacturing questions.
Corrective action and negotiated resolution
Developing remediation that can be documented and tested, and evaluating or negotiating Memorandum of Agreement terms that may affect the pharmacy’s operations for years.
Order to Show Cause, Immediate Suspension Order, and civil penalty defense
Representing the pharmacy in formal DEA administrative proceedings and addressing civil penalty exposure in parallel. Where criminal exposure or another parallel federal issue exists, Jani Law PLLC can coordinate the DEA regulatory defense with separately retained counsel so the positions taken in one matter do not unnecessarily create problems in another.
Compounding Pharmacy DEA Defense FAQs
These answers provide general orientation only. The significance of a DEA inspection, audit finding, subpoena, or registration issue depends on the facts, the authority DEA is using, the pharmacy’s records, and the law that applies to the particular matter.
It depends on the authority being used. DEA regulations contemplate administrative inspections conducted with informed consent, with an administrative inspection warrant, and in certain circumstances where a warrant is not required. If investigators are requesting consent, the legal and practical considerations can be fact-specific.
For an administrative inspection, DEA personnel generally state the purpose of the inspection and present credentials and written inspection authority. That stated purpose may not reveal every piece of information DEA already has, whether another person or entity is part of the inquiry, or how the matter may develop after the records are reviewed.
Potentially. An administrative inspection may remain limited to routine regulatory review, or information developed during the inspection may lead DEA to examine additional records, controlled substances, dispensing practices, prescriber relationships, or registration issues. Public enforcement matters involving pharmacies and compounding operations illustrate why the records uncovered during an inspection can matter more than the label placed on the visit at the outset.
In general, an accountability audit reconstructs selected controlled substances over a defined period. The analysis may compare beginning inventory and receipts against dispensing, distribution, transfers, destruction, documented losses, and ending physical inventory. At a compounding pharmacy, batch quantities, yields, wastage, unit conversions, and data from multiple systems may become important to that reconstruction.
Not necessarily. The significance of an apparent discrepancy can depend on the controlled substance and quantity involved, the time period, the quality of the underlying records, whether the issue appears isolated or systemic, the pharmacy’s compliance history, the explanation supported by the source records, and the legal theory DEA ultimately pursues. An audit number is a starting point for analysis, not a substitute for the underlying evidence.
The analysis turns on the pharmacy’s actual controlled-substance activity, not simply on the fact that it compounds or on whether it operates under FDA Section 503A or 503B. Relevant facts can include how the controlled substance is compounded, the relationship to dispensing or administration, who receives the finished product, which entities and locations are involved, and whether transfers to other registrants also raise distribution questions.
Yes. A DEA administrative subpoena can seek records concerning a prescriber even when the pharmacy is initially only a records source. The production can nevertheless raise separate questions if the records reveal issues involving the pharmacy’s own dispensing, due diligence, or controlled-substance handling. Jani Law’s guide to DEA administrative subpoenas discusses the subpoena process in more detail.
No single fact answers that question in the abstract. Facts that cause a pharmacist to question a prescription can be relevant evidence, but the significance of those facts depends on the prescription, what information was available, what the pharmacist did with that information, the governing law, and the violation DEA is actually alleging.
There is no reliable general answer. The analysis can depend on what the investigation concerns, what the pharmacy knows about the platform and prescribers, its own due diligence, the prescriptions it is receiving, and any unresolved issues in the dispensing record. A pharmacy facing that decision may want advice based on the specific facts rather than relying on general assurances about the platform’s compliance model.
At that point the matter has moved from investigation into formal administrative proceedings involving the DEA registration. The current rules generally provide a 30-day period from service to request a hearing and file the required response, but the controlling deadlines are the ones stated in the documents actually served. Jani Law’s Order to Show Cause guide explains the transition from investigation to formal DEA litigation.
DEA Contacted Your Compounding Pharmacy? Talk With Jani Law PLLC.
A pharmacy owner or PIC often calls before anyone knows exactly where the matter is going. DEA may be reviewing inventory, asking about a prescriber, examining practitioner-office transactions, or seeking records. The immediate task is to understand what the agency is examining and what the existing record actually shows.
The value of early DEA regulatory counsel is perspective. A pharmacy may experience an inventory variance, a subpoena, and questions about a prescriber as separate events. DEA may be evaluating those facts together. Understanding the broader picture can matter before the pharmacy commits to explanations, record productions, corrective positions, or a resolution strategy.
Dhairya Jani served as DEA Diversion Enforcement Counsel before founding Jani Law PLLC. The firm provides DEA regulatory defense to pharmacies, prescribers, clinics, distributors, manufacturers, and other registrants nationwide, from the first inspection or accountability audit through administrative subpoenas, investigations, voluntary disclosures, civil penalty matters, Memorandum of Agreement negotiation and compliance, Orders to Show Cause, Immediate Suspension Orders, and hearings before DEA Administrative Law Judges.
Representation is subject to applicable professional and admission requirements.
The initial consultation is free and confidential. Call 202-899-2711 or contact Jani Law PLLC online to discuss the DEA matter directly with Dhairya Jani.